Search Result

Pathways Recommended:	PROTAC

Results for "

PROTAC EGFR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (44) Ligands for Target Protein for PROTAC (6) PROTAC Linkers (4) Akt (1) Anaplastic lymphoma kinase (ALK) (4) Apoptosis (10) ATP Synthase (1) Autophagy (1) Caspase (1) CDK (1) Cytochrome P450 (1) E3 Ligase Ligand-Linker Conjugates (5) ERK (1) Estrogen Receptor/ERR (1) FAK (2) Ligands for E3 Ligase (1) PARP (4) PROTACs (38) Target Protein Ligand-Linker Conjugates (4)
By Research Areas:	Cancer (57) Infection (1) Inflammation/Immunology (2)
Click Chemistry:	PROTAC Synthesis (2) Alkynes (2)

Inhibitors & Agonists

Click Chemistry

Targets Recommended: PROTAC-Linker Conjugates for PAC PROTAC Linkers EGFR Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-123921

Gefitinib-based PROTAC 3 3 Publications Verification	PROTACs EGFR	Cancer
Gefitinib-based PROTAC 3, conjugating an *EGFR* binding element to a von Hippel-Lindau ligand via a linker, induces *EGFR* degradation with DC₅₀s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively .

HY-156698

HJM-561	PROTACs EGFR	Cancer
HJM-561 is a selective and effective orally active *EGFR* *PROTAC* degrader. HJM-561 is able to overcome the triple EGFR mutations that are resistant to Osimertinib (HY-15772). HJM-561 exhibits potent degradation of EGFR Del19/T790M/C797S (DC₅₀: 9.2 nM) and L858R/T790M/C797S (DC₅₀: 5.8 nM), and has anti-tumor activity (pink: EGFR ligand (HY-12857); blue: CRBN ligand (HY-A0003); black: linker) .

HY-147858

PROTAC EGFR degrader 7	PROTACs EGFR Apoptosis	Cancer
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR ^L858R/T790M degrader, with a DC₅₀ of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC₅₀ of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-141640

MS154	PROTACs EGFR	Cancer
MS154 is a first-in-class E3 ligase cereblon-recruited EGFR degrader with K_d values of 1.8 nM and 3.8 nM for EGFR ^WT and EGFR ^L858R mutant, respectively. MS154 potently induces degradation of mutant, but not wild-type, EGFR in cancer cell lines in an E3 ligase-dependent manner. MS154 exhibits anticancer effects against lung cancer (blue: E3 ligase ligand (HY-103596); black: linker (HY-W096167); pink: EGFR ligand (HY-168305)) .

HY-131864

SJF-1528	PROTACs EGFR	Cancer
SJF-1528 (PROTAC 1) is a potent *EGFR* PROTAC degrader with DC₅₀ values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutant EGFR in HeLa cells. SJF-1528 also degrades HER2. SJF-1528 promotes ubiquitination and degradation of EGFR and can be used in breast cancer research (Pink: ligand for target protein (HY-159047); Black: linker Tos-PEG2-CH2-Boc (HY-130532); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .

HY-130549

Acid-PEG3-C2-Boc	PROTAC Linkers	Cancer
Acid-PEG3-C2-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs for the degradation of EGFR and inhibition of mTOR .

HY-146349

PROTAC EGFR degrader 4	PROTACs EGFR Autophagy	Cancer
PROTAC EGFR degrader 4 is a potent *PROTAC* targeting mutant *EGFR*.PROTAC EGFR degrader 4 induces EGFR ^del19 and EGFR ^L858R/T790M degradation with DC₅₀s of 0.51 and 126 nM, respectively. PROTAC EGFR degrader 4 significantly inhibits growth of HCC827 and H1975 cell lines with IC₅₀s of 0.83 and 203.1 nM, respectively. Induced EGFR degradation is related to autophagy .

HY-161536

PROTAC EGFR degrader 9	PROTACs EGFR Apoptosis	Cancer
PROTAC EGFR degrader 9 (Compound C6) is an orally active CRBN-based PROTAC EGFR degrader. PROTAC EGFR degrader 9 exhibits a DC₅₀ of 10.2 nM and a K_d of 240.2 nM against EGFR ^{L858R/T790M/C797S}. PROTAC EGFR degrader 9 exhibits potent degradation activity against various EGFR mutants, while sparing the EGFRWT. (Blue: CRBN ligand (HY-A0003), Black: linker (HY-161613); Pink: EGFR inhibitor (HY-161537)) .

HY-175839

PROTAC EGFR degrader 15	PROTACs EGFR ATP Synthase	Cancer
PROTAC EGFR degrader 15 is a Pomalidomide (HY-10984)-based Gefitinib (HY-50895) **EGFR PROTAC** degrader. PROTAC EGFR degrader 15 triggers EGFR degradation via ubiquitin-proteasome-dependent proteolysis and autophagy-lysosome activation pathways. PROTAC EGFR degrader 15 targets ETFA to enhance ATP production. PROTAC EGFR degrader 15 significantly suppresses tumor growth in a Gefitinib-acquired resistant HCC-827 xenograft model. PROTAC EGFR degrader 15 can be used for the study of non-small cell lung cancer (NSCLC) (Pink: EGFR ligand (HY-W109039); Blue: CRBN ligand (HY-10984); Black: Linker (HY-W679737)) .

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	PARP Ligands for Target Protein for PROTAC	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .

HY-157581

MS39	EGFR PROTACs	Cancer
MS39 (compound 6) is a *PROTAC* targeting *EGFR. MS39 reduces the expression of EGFR* and downstream signaling in HCC-827 and H3255 cells. MS39 inhibits the proliferation of H3255 cells .

HY-131865

SJF-1521	PROTACs EGFR	Cancer
SJF-1521 is a selective **EGFR PROTAC degrader. SJF-1521 is capable of inducing EGFR** degradation in OVCAR8 cells. SJF-1521 can be used for tumor research. (Pink: EGFR ligand (HY-177379); Black: Linker (HY-128804); Blue: VHL Ligand (HY-125845)) .

HY-175252

PROTAC EGFR degrader 14	PROTACs EGFR Apoptosis	Cancer
PROTAC EGFR degrader 14 is a potent and selective EGFR PROTACdegrader with a DC₅₀ of about 2.9 nM and a D_max of 93.1% for EGFR ^{L858R/T790M/C797S}. PROTAC EGFR degrader 14 selectively induces EGFR ^C797S degradation through a VHL and proteasome-dependent manner and downregulated EGFR-associated transcriptome and exhibits good selectivity over EGFR ^WT. PROTAC EGFR degrader 14 induces cell cycle arrest and apoptosis and significantly inhibits tumor growth. PROTAC EGFR degrader 14 can be used for the study of nonsmall cell lung cancer (NSCLC) (Pink: Target protein ligand: (HY-143337); Blue: E3 ligand (HY-125845); Black: Linker (HY-W004688)) .

HY-144304

PROTAC EGFR degrader 2	PROTACs EGFR	Cancer
PROTAC EGFR degrader 2 is a potent PROTAC *EGFR* degrader. PROTAC EGFR degrader 2 exhibits excellent antiproliferative activity with IC₅₀ of 4.0 nM and good EGFR degradation activity with DC50 of 36.51 nM. PROTAC EGFR degrader 2 can be used for the synthesis of nitroreductase (NTR)-responsive PROTAC .

HY-139997

DDC-01-163	PROTACs EGFR	Cancer
DDC-01-163 is an allosteric *PROTAC* degrader targeting *EGFR. DDC-01-163 is dependent on the ubiquitin–proteasome system. DDC-01-163 can selectively inhibit the proliferation of L858R/T790M (L/T) mutant Ba/F3 cells. DDC-01-163 is effective against Osimertinib (HY-15772)-resistant cells with L/T/C797S and L/T/L718Q EGFR* mutations. DDC-01-163 exhibits enhanced anti-proliferative activity against L858R/T790M EGFR-Ba/F3 cells when combined with the ATP-site EGFR inhibitor Osimertinib. DDC-01-163 can be used for the study of non-small cell lung cancer .

HY-161633

PROTAC EGFR degrader 11	PROTACs EGFR FAK	Cancer
PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader for epidermal growth factor receptor (EGFR), with DC₅₀ <100 nM. PROTAC EGFR degrader 11 binds CRBN-DDB1 with a K_i of 36 nM. PROTAC EGFR degrader 11 degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibits the proliferation of BaF3 wild type and EGFR mutants, with IC₅₀ <100 nM.

HY-153901

PROTAC EGFR degrader 8	EGFR PROTACs	Cancer
PROTAC EGFR degrader 8 (T-184) is a *PROTAC* *EGFR* degrader. PROTAC EGFR degrader 8 degrades EGFR in HCC827 cell with a DC₅₀ of 15.56 nM. PROTAC EGFR degrader 8 inhibits H1975, PC-9, HCC827 cell growth with IC₅₀s of 7.72 nM, 121.9 nM, 14.21 nM. PROTAC EGFR degrader 8 can be used for research of cancer, especially NSCLC .

HY-178861

dCDK9-202	PROTACs CDK Caspase PARP Apoptosis	Cancer
dCDK9-202 a potent CDK9 PROTAC degrader with an DC₅₀ value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma (Pink: CDK9 ligand (HY-178862); Blue: CRBN ligand (HY-W248665); Black: Linker (HY-N8015)) .

HY-161537

EGFR ligand-9	EGFR	Cancer
EGFR ligand-9 is an *EGFR* ligand. EGFR ligand-9 can be used for synthesis of PROTAC EGFR degrader 9 (HY-161536) .

HY-147942

MS9449	PROTACs EGFR	Cancer
MS9449 is a potent **PROTAC EGFR degrader with K_d*s of 17 nM and 10 nM for EGFR* WT and EGFR L858R, respectively. MS9449 effectively induces degradation of mutant EGFRs through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. MS9449 potently inhibits the proliferation of NSCLC cells. MS9449 can be used for researching anticancer .

HY-147941

MS9427	PROTACs EGFR	Inflammation/Immunology Cancer
MS9427 is a potent **PROTAC EGFR degrader with K_d*s of 7.1 nM and 4.3 nM for EGFR* WT and EGFR L858R, respectively. MS9427 selectively degrades the mutant but not the WT EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. MS9427 potently inhibits the proliferation of NSCLC cells. MS9427 can be used for researching anticancer .

HY-157579

MS154N	PROTACs EGFR	Cancer
MS154N (compound 28) is the negative control of MS39 (HY-157581). MS154N is composed of PROTAC target protein ligand EGFR ligand-11 (HY-168305) (red part), E3 ligase ligand 4-Hydroxy-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (HY-W441376) (blue part) and PROTAC Linker 8-Iodooctan-1-amine (HY-168306) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Me-Thalidomide-O-C8-NH2 (HY-168307) .

HY-178242

PROTAC EGFR degrader 16	PROTACs EGFR	Cancer
PROTAC EGFR degrader 16 (Compound 98) a selective **EGFR PROTAC degrader with DC₅₀ values of < 50 nM in NCI-H1975 (EGFR L858R-T970M), NCI-H3225 (EGFR L858R) and NCI-H1976 + CS (EGFR L858R-T970M-L797S*). PROTAC* EGFR degrader 16 can be used for the study of EGFR-driven cancerssuch as non-small cell lung cancer (Pink: EGFR ligand (HY-178313); Blue: CRBN ligand (HY-W1128702); Black: Linker; EGFR ligand + Linker (HY-178311)) .

HY-147219A

SIAIS164018 hydrochloride	PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis	Cancer
SIAIS164018 hydrochloride is a *PROTAC*-based ALK and *EGFR* degrader, with IC₅₀ value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 hydrochloride strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 hydrochloride exhibits better property than Brigatinib (HY-12857) .

HY-144605

PROTAC EGFR degrader 3	EGFR PROTACs	Cancer
PROTAC EGFR degrader 3 is a potent *PROTAC* *EGFR* degrader. PROTAC EGFR degrader 3 shows excellent cellular activity against the H1975 and HCC827 cells with high selectively. PROTAC EGFR degrader 3 shows that the lysosome is involved in the degradation process of EGFR mutant degradation .

HY-171958

PROTAC EGFR degrader 12	PROTACs EGFR	Cancer
PROTAC EGFR degrader 12 (example 1) is a *PROTAC* degrader targeting *EGFR* that can effectively degrade EGFR mutants, but has little effect on EGFR WT. PROTAC EGFR degrader 12 shows IC_{50_{s against EGFR ^L858R-T790M (NCI-H1975 cells), EGFR ^L858R (NCI-H3255 cells), and EGFR ^{L858R-T790M-L797S} (NCI-H1975+CS cells) of all <50 nM .}}

HY-141481

DP-C-4	PROTACs EGFR PARP	Cancer
DP-C-4 is a Cereblon-based dual *PROTAC* for simultaneous degradation of *EGFR* and PARP .

HY-147941A

MS9427 TFA	PROTACs EGFR	Infection Inflammation/Immunology Cancer
MS9427 TFA is a potent **PROTAC EGFR degrader with K_d*s of 7.1 nM and 4.3 nM for EGFR* WT and EGFR L858R, respectively. MS9427 TFA selectively degrades the mutant but not the WT EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. MS9427 TFA potently inhibits the proliferation of NSCLC cells. MS9427 TFA can be used for researching anticancer .

HY-147219

SIAIS164018	PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis	Cancer
SIAIS164018 is a *PROTAC*-based ALK and *EGFR* degrader, with IC₅₀ value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 exhibits better property than Brigatinib (HY-12857) .

HY-161632

PROTAC EGFR degrader 10	PROTACs EGFR FAK	Cancer
PROTAC EGFR degrader 10 (Compound B56) is a PROTAC degrader for epidermal growth factor receptor (EGFR), with DC₅₀ <100 nM. PROTAC EGFR degrader 10 binds CRBN-DDB1 with a K_i of 37 nM. PROTAC EGFR degrader 10 degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibits the proliferation of BaF3 wild type and EGFR mutants, with IC₅₀ <150 nM .

HY-146423

PROTAC EGFR degrader 6	PROTACs EGFR Apoptosis	Cancer
PROTAC EGFR degrader 6, a **PROTAC EGFR** degrader, potently degrades EGFR ^Del19 in HCC827 cells with the DC₅₀ of 45.2 nM. PROTAC EGFR degrader 6 significantly induces the apoptosis of HCC827 cells and arrest the cells in G1 phase .

HY-146422

PROTAC EGFR degrader 5	PROTACs EGFR Apoptosis	Cancer
PROTAC EGFR degrader 5 (Compound 10), a **PROTAC EGFR** degrader, potently degrades EGFR ^Del19 in HCC827 cells with the DC₅₀ of 34.8 nM. PROTAC EGFR degrader 5 significantly induces the apoptosis of HCC827 cells and arrest the cells in G1 phase .

HY-158313

PROTAC EGFR degrader 13	EGFR PROTACs	Cancer
PROTAC EGFR degrader 13 (compound 106) is an **EGFR PROTAC degrader with a DC₅₀** of <0.1 μM. PROTAC EGFR degrader 13 has proliferation inhibitory activity on cell Ba/F3-TEL-EGFR-T790M-L858R-C797S with an IC₅₀ of 15.6 nM. PROTAC EGFR degrader 13 can be used for the study of EGFR-related diseases such as cancer (Pink: Target protein ligand; Blue: E3 ligand (HY-14658); Black: linker (HY-W262798); E3 ligand + linker: HY-W998306) .

HY-150905

EGFR ligand-2	EGFR	Cancer
EGFR ligand-2 (compound C4), a covalent *EGFR* ligand, is a EGFR mutant inhibitor with IC₅₀s of 21 nM and 48 nM for EGFR ^L858R and EGFR ^L858R/T790M, respectively. EGFR ligand-2 can be used to synthesize PROTAC .

HY-178311

EGFR Ligand-Linker Conjugates 4	Target Protein Ligand-Linker Conjugates EGFR	Cancer
EGFR Ligand-Linker Conjugates 4 is a conjugate of the EGFR ligand (HY-178313) and the linker. EGFR Ligand-Linker Conjugates 4 can be used for synthesizing PROTAC EGFR degrader 16 (HY-178242) .

HY-178313

EGFR ligand-18	Ligands for Target Protein for PROTAC EGFR	Cancer
EGFR ligand-18 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC EGFR degrader 16 (HY-178242). PROTAC EGFR degrader 16 is a potent **EGFR PROTAC** degrader with anti-tumor activity .

HY-175887

Pomalidomide-C9-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C9-Br is a synthesized E3 ligase ligand-linker conjugate that can be used to synthesize PROTAC EGFR degrader 15 (HY-175839). PROTAC EGFR degrader 15 is a potent **EGFR PROTAC** degrader with anti-cancer activity .

HY-176788

EGFR Ligand-Linker Conjugates 1	Target Protein Ligand-Linker Conjugates EGFR	Cancer
EGFR Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for *EGFR* (HY-150905) and a PROTAC linker, which recruits E3 ligases. EGFR Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC EGFR degrader 3 (HY-144605) .

HY-156700

Lenalidomide-acetylene-Br	PROTAC Linkers	Cancer
Lenalidomide-acetylene-Br is a PROTAC Linker taht makes up HJM-561 (HY-156698). HJM-561 is a potent, selective, and orally active EGFR PROTAC to inhiibit Osimertinib (HY-15772)-resistant EGFR triple mutations.

HY-W262798

1-(Piperidin-4-ylmethyl)piperazine PMP	PROTAC Linkers	Cancer
1-(Piperidin-4-ylmethyl)piperazine is a PROTAC linker. 1-(Piperidin-4-ylmethyl)piperazine can be used to design PROTAC, such as PROTAC EGFR degrader 13 (HY-158313) .

HY-131864A

SJF-1528 hemihydrate	PROTACs EGFR	Cancer
SJF-1528 (PROTAC 1) hemihydrate is a potent *EGFR* PROTAC degrader with DC₅₀ values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutant EGFR in HeLa cells. SJF-1528 hemihydrate also degrades HER2. SJF-1528 hemihydrate promotes ubiquitination and degradation of EGFR and can be used in breast cancer research (Pink: ligand for target protein (HY-159047); Black: linker Tos-PEG2-CH2-Boc (HY-130532); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .

HY-174415

ZSH-2117	PROTACs EGFR Akt ERK	Cancer
ZSH-2117 is a covalent and selective *EGFR* *PROTAC* degrader with a DC₅₀ of 45 nM in Ba/F3-EGFR ^{L858R/T790M/C797S} cells. ZSH-2117 significantly inhibits cell proliferation and reduces the downstream EGFR signaling proteins level of AKT and ERK. ZSH-2117 effectively inhibits tumor growth in Ba/F3-EGFR ^{L858R/T790M/C797S} xenograft mice model . Pink: EGFR ligand (HY-175162); Blue: NEDD4 ligase ligand (HY-175159); Black: linker

HY-141486A

PROTAC PARP/EGFR ligand 1	PARP EGFR Ligands for Target Protein for PROTAC	Others
PROTAC PARP/EGFR ligand 1 is an active compound that can be used for the synthesis of dual PARP EGFR degraders by proteolytic targeting chimera *(PROTAC)* technology .

HY-141486

*(Rac)-PROTAC* PARP/EGFR ligand 1**	Target Protein Ligand-Linker Conjugates	Cancer
(Rac)-PROTAC PARP/EGFR ligand 1 incorporates a ligand for PARP and EGFR , and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). (Rac)-PROTAC PARP/EGFR ligand 1 can be used in the synthesis of DP-C-4, which is CRBN-based dual PROTAC for simultaneous degradation of EGFR and PARP .

HY-147858A

PROTAC EGFR degrader 7 diTFA	PROTACs	Cancer
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFRL858R/T790M degrader, with a DC₅₀ of 13 .2 nM.PROTAC EGFR degrader 7 inhibits NCI-H1975 cells proliferation, with an IC₅₀ of 46 .82 nM.PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI-H1975 cell.PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research .

HY-175255

EGFR-IN-47-C6-COOMe	Target Protein Ligand-Linker Conjugates	Cancer
EGFR-IN-47-C6-COOMe is a synthesized target protein ligand-linker conjugate that can be used for synthesis of PROTACs, such as PROTAC EGFR degrader 14 (HY-175252). PROTAC EGFR degrader 14 is a EGFR PROTAC degrader with anti-tumor activity .

HY-161538

Lenalidomide-C6-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-C6-Br is a conjugate of E3 ligase ligand and linker. Lenalidomide-C6-Br can be utilized for synthesis of PROTAC EGFR degrader 9 (HY-161536) .

HY-168305

EGFR ligand-11	Ligands for Target Protein for PROTAC EGFR	Cancer
EGFR ligand-11 is a target protein ligand for *EGFR* and can be used to synthesize *PROTAC* MS154 (HY-141640) .

HY-161613

7-Bromoheptanoyl chloride	PROTAC Linkers	Cancer
7-Bromoheptanoyl chloride is a linker of PROTAC EGFR degrader 9 (HY-161536) .

HY-170350

Pomalidomide-PEG2-OMs	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG2-Oms (CRBN ligand Pomalidomide (HY-10984)) is an E3 Ligase Ligand-Linker Conjugate for EGFR PROTAC DDC-01-163 (HY-139997) .

Cat. No.	Product Name		Classification

HY-147858

PROTAC EGFR degrader 7		Alkynes PROTAC Synthesis
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR ^L858R/T790M degrader, with a DC₅₀ of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC₅₀ of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-175948

Lenalidomide-CO-C3-NH-alkynes		Alkynes PROTAC Synthesis
Lenalidomide-CO-C3-NH-alkynes is an E3 ligase ligand-linker conjugate comprising Lenalidomide (HY-A0003) and a linker. Acepromazine-1-piperazinepropanamine dihydrochloride can be conjugated to a target protein ligand to form a PROTAC molecule—for instance, the PROTAC EGFR degrader 7 (HY-147858) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: